Choroideremia, Geographic Atrophy from Age-related Macular Degeneration, Retinal Dystrophies, Retinitis Pigmentosa, Stargardt Disease, Stargardt Macular Dystrophy, X-lined Retinoschisis
Conditions
Brief summary
The Vision Research and Assessment Institute (VRAI) was established with the purpose of serving as a testing facility for efficacy endpoints for patients with Low Vision. The mission of the VRAI is to enable the highest quality, standardized efficacy testing of patients with visual impairment. The VRAI facilitates the development and refinement of existing endpoints specifically for testing patients with Low Vision.
Detailed description
The VRAI is a state-of-the-art research institute specifically for patients with low or very low vision due to diseases of the retina of the eye. The Institute is staffed by highly experienced Low Vision specialists and provides a comfortable, familiar environment for patient testing. The study is a non-interventional prospective cohort study of up to 40 patients for each disease condition (Retinitis Pigmentosa, Choroideremia, Stargardt Macular Dystrophy, Geographic Atrophy from Age-related Macular Degeneration, X-linked Retinoschisis or other retinal dystrophies ). Patients are scheduled for an initial visit where they are tested on a series of efficacy tests. Thereafter, patients will be invited to attend for a further visit up to two weeks and then periodically for up to one year. The objectives of the study are to evaluate how well patients use their vision, how the tests relate to activities of daily living, establish clinical meaningfulness, assess the impact of disease progression and the precision and accuracy of each test in the context of their eye condition.
Interventions
None listed
Sponsors
Ray Therapeutics, Inc.
The Vision Research and Assessment Institute (VRAI)
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Diagnosis of bilateral retinitis pigmentosa, choroideremia, Stargardt macular dystrophy, geographic atrophy from age-related macular degeneration, X-linked retinoschisis or other retinal dystrophies confirmed from previous eye examination records * Best-corrected visual acuity between 20/70 and HM in at least one eye as tested with clinic-based visual acuity method * Reasonably fluent in English
Exclusion criteria
* Cognitive impairment, memory loss or dementia sufficient in severity to preclude informed consent or in the opinion of the investigator would prevent satisfactory completion of some or all of the testing. * Any circumstance that in the opinion of the investigator, would interfere with participation in, or compliance with the study protocol * Current pregnancy as reported by patient
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Operational feasibility of testing moderate to profound vision impaired patients with various retinal dystrophies on a battery of visual assessments | 3 months | Determining how many patients in the visual range 20/70 - HM (depending upon indication) can perform specific tests of visual function with a measurable score. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| To quantify patient-based measurement properties of each test modality (for the purposes of endpoint qualification) | 2 years | Test-retest reliability on the same visit or on two different testing sessions on different days including determination of significant learning effects or other scoring variables that impact variability. |
| To quantify assessor-based measurement properties of each test modality (for the purposes of endpoint qualification) | 2 years | Intra- and inter-grader variability for scoring of tests by test graders/raters. Assessments incorporating independent graders/raters will be assessed for within session and across session scoring reliability to ensure consistent methods. |
Countries
United States
Contacts
Primary ContactShawn Yu, OD
Outcome results
None listed